Table 1.
PYR41 dosing regimen.
| Group | Day of treatment | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
| WT | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle |
| (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | |
| hAPP | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle | Vehicle |
| (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | |
| hAPP- | PYR41 | Vehicle | Vehicle | PYR41 | Vehicle | Vehicle | PYR41 | Vehicle | Vehicle | PYR41 | Vehicle | Vehicle | PYR41 | Vehicle |
| PYR41 | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) |
| hAPP- | PYR41 | CSA | CSA | PYR41 | CSA | CSA | PYR41 | CSA | CSA | PYR41 | CSA | CSA | PYR41 | CSA |
| PYR41/ | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) | (po) | (ip) | (po) |
| CSA | ||||||||||||||
The present dosing regimen was based on a 2-week preliminary dosing study with CD-1 mice (data not shown). WT and hAPP mice were treated according to the following dosing scheme over the course of 14 days: WT and hAPP mice were given vehicle p.o. by oral gavage or by i.p. injection once every 3 days. hAPP-PYR41 mice received 2 mg/kg PYR41 by i.p. injection once every 3 days and vehicle p.o. by oral gavage on all other days. hAPP-PYR41/CSA mice received 2 mg/kg PYR41 by i.p. injection once every 3 days and 25 mg/kg CSA p.o. by oral gavage on all other days.